In the coming years, European death rates because of cancer will further decline, but the overall number of cases will increase, mostly as a consequence of the ageing of the population. The target for cancer prevention in Europe will remain a healthy diet and control of obesity in addition to a decrease in smoking. A healthy diet model in European countries is the traditional Mediterranean diet, which is based on abundant and variable plant foods, high consumption of cereals, olive oil as the main (added) fat, low intake of (red) meat and moderate consumption of wine. The Mediterranean diet is associated with a reduced risk of cardiovascular disease and cancer. The biological mechanisms for cancer prevention associated with the Mediterranean diet have been related to the favourable effect of a balanced ratio of omega 6 and omega 3 essential fatty acids and high amounts of fibre, antioxidants and polyphenols found in fruit, vegetables, olive oil and wine. The Mediterranean diet also involves a ‘Mediterranean way of drinking’, that is, regular, moderate consumption of wine mainly with food. This pattern of drinking increases longevity, reduces the risk of cardiovascular disease and does not appreciably influence the overall risk of cancer. However, heavy alcohol drinking is associated with digestive, upper respiratory tract, liver and breast cancers; therefore, avoidance or restriction of alcohol consumption to two drinks/day in men and one drink/day in women is a global public health priority.
aDepartment of Surgery, University of Genoa, Genoa
bDepartment of Gastroenterology, Policlinico di Monza, Monza
cDepartment of Biology, University of Pisa, Pisa
dCRA-Research Centre for Viticulture, Conegliano
eDi Va PRA, Microbiology and Food Technology Sector, University of Turin, Turin
fMario Negri Institute for Pharmacological Research
gDepartment of Occupational Health, University of Milan
iDepartment of Biotechnology, University of Verona, Verona
jDepartment of Applied Health Science, University of Pavia
kASP (Azienda di Servizi alla Persona) of Pavia, Pavia, Italy
lDivision of Surgery and Interventional Science, Faculty of Medical Science, University College London, London
mLady Sobell Gastrointestinal Unit, Wexham Park Hospital, Slough, UK
nEuropean Cancer Prevention Organization, Hasselt
oInBioVeritas, Schilde, Belgium
Correspondence to Attilio Giacosa, MD, PhD, Department of Gastroenterology, Policlinico di Monza, Via Amati 111, Monza 20900, Italy Tel: +30 329 926 2099; fax: +39 010 587 341; e-mail: email@example.com
Received April 4, 2012
Accepted April 6, 2012
Cancer incidence and trends in Europe
Although more than 40% of cancer deaths can be prevented, cancer represents the second most important cause of death and morbidity in Europe, with more than three million new cases and 1.7 million deaths each year. On a global scale, cancer accounted for 7.4 million deaths (around 13% of the total) in 2004. Around one-quarter of all cancer cases occurred in Europe, which accounts for only one-eighth of the world population. Tobacco and excessive alcohol consumption cause about one-third of the total cancer burden, with precise figures varying from country to country. If the consequences of an inappropriate diet, obesity and insufficient physical activity are included, the percentage of cancers because of an unhealthy lifestyle increases to 40%. Lung, colon and breast cancer result in the highest number of cancer deaths each year in Europe and tobacco use is the single most important risk factor for cancer (www.euro.who.int/en/what-we-do/health-topics/noncommunicable-diseases/cancer/facts-and-figures,2010). Not only does Europe have a wide range in incidence of all common cancers, it also has a wide range in dietary patterns, environmental exposures and social behaviour. Europe offers an ideal ‘laboratory’ for the formulation and testing of hypotheses on the causation of human cancers. The highest incidence of cancer in Europe is found for colon and rectum, breast, lung (with the highest mortality), prostate, stomach (high mortality), bladder (some problems with differences in coding in different countries), pancreas (very high mortality), head and neck, kidney and non-Hodgkin lymphoma (Ferlay et al., 2010). Lung, cervix and stomach cancer are more common in South and Central Europe. Scandinavia appears to have incidences similar to the UK and Denmark. Colorectal cancer is stable/increasing because of changing nutritional habits and obesity in countries with a traditionally low incidence and mortality. Melanomas, prostate, testicular, female lung and breast cancer incidences are increasing (the latter two are because of increased smoking and changing reproductive patterns, respectively). Larynx, ovarian and bladder cancer are stable or decreasing. Consistent decreases have been observed for gastric, cervical and male lung cancer because of improved food preservation, improved personal hygiene and Helicobacter pylori eradication, screening programmes and decreased male smoking, respectively (Karim-Kos et al., 2008; Ferlay et al., 2010). The latter two are the major factors influencing the observed trends of death because of cancer. In the coming years, European cancer death rates may decline further, but the overall number of cases will increase, mostly as a consequence of increasing smoking among women, increasing obesity and ageing (La Vecchia, 2011). Therefore, the next target for cancer prevention in Europe will involve the adoption of a healthy diet and control of obesity in addition to a decrease in smoking habits.
Obesity and cancer
Ample evidence has been collected to show a positive correlation between excess body weight and an increased risk of cancers of the breast (postmenopausal), colon, endometrium, gallbladder, adenocarcinoma of the oesophagus, gastric cardia, kidney and pancreas.
Adipose tissue is an active endocrine organ. The mechanisms by which adipose tissue may influence the risk of cancer are production of sex steroid hormones (e.g. oestrogen, androgen), effects on insulin sensitivity and the production of insulin-like growth factors, actions on other hormones in adipose tissue (e.g. leptin, adiponectin) and increases in oxidative stress and chronic low-grade inflammation that affect the body’s immune response (Van Kruijsdijk et al., 2009). In obesity, increased release from adipose tissue of free fatty acids, tumour-necrosis factor-α and resistin, and reduced release of adiponectin lead to the development of insulin resistance and compensatory, chronic hyperinsulinaemia. Increased insulin levels, in turn, lead to reduced liver synthesis and blood levels of insulin-like growth factor-binding protein 1 (IGFBP1) and probably also reduce IGFBP1 synthesis locally in other tissues. Increased fasting levels of insulin in the plasma are also generally associated with reduced levels of IGFBP2 in the blood. This results in increased levels of bioavailable IGF1. Insulin and IGF1 signals through the insulin receptors and the IGF1 receptor, respectively, promote cellular proliferation and inhibit apoptosis in many tissue types. These effects might contribute to cancerogenesis (Calle and Kaaks, 2004). Moreover, adipose tissue produces the enzymes aromatase and 17β-hydroxysteroid dehydrogenase. Therefore, in obese individuals, there is typically an increased conversion of the androgens Δ4-androstenedione (Δ4A) and testosterone (T) into the oestrogens oestrone (E1) and oestradiol (E2), respectively, by aromatase. 17β-Hydroxysteroid dehydrogenase converts the less biologically active hormones Δ4A and E1 into the more active hormones T and E2, respectively. In parallel, obesity leads to hyperinsulinaemia, which in turn causes a reduction in the hepatic synthesis and circulating levels of sex-hormone-binding globulin. The combined effect of increased formation of oestrone and testosterone, along with reduced levels of sex-hormone-binding globulin, leads to an increase in the bioavailable (free) fractions of E2 and T that can diffuse to target cells, where they bind to oestrogen and androgen receptors. The effects of sex steroids binding to their receptors can vary depending on the tissue types, but in some tissues (e.g. breast epithelium and endometrium), they promote cellular proliferation and inhibit apoptosis (Calle and Kaaks, 2004).
Obesity is the second (to tobacco) leading risk factor for cancer in North America. Further, it has important public health implications for chronic diseases such as type 2 diabetes, orthopaedic malformations, hypertension, cardiovascular diseases and cancer. Future research should focus on how the risk of cancer is affected by successful and sustained weight loss.
Mediterranean diet and cancer
A healthy diet model in European countries is the traditional Mediterranean diet, which is based on abundant and variable plant foods, high consumption of cereals, olive oil as the main (added) fat, low intake of (red) meat and moderate consumption of wine. A diet rich in fruit and vegetables protects against common epithelial cancers, including in particular those of the digestive tract. The intake of whole-grain food has been consistently related to a reduced risk of colorectal cancer and other neoplasms (Aune et al., 2011). Several case–control studies have reported a favourable effect of fibre on colon and rectal cancers; in contrast, intake of refined grains has been associated with an increased risk of stomach, colorectal and upper digestive tract cancers in studies conducted in Mediterranean populations. Refined cereals and sugar are responsible for glycaemic overload and insulin resistance and this may lead to cellular growth promotion through specific hormones or IGFs. The role of fats, and of specific types of fats, in the risk of breast and colorectal cancers, as well as of several other cancers, remains a major open question (Hu et al., 2011a). In a large study from Italy, isocaloric substitution of 5% of the total calories from saturated fats by unsaturated ones was associated with reductions in the risk of breast (odds ratio=0.67) and colorectal (odds ratio=0.78) cancer (La Vecchia et al., 1998). The use of olive oil instead of butter and other added fats appears to result in a decrease in the risk of various common cancers. In particular, there is suggestive evidence of a favourable effect on the risk of cancers of the upper aerodigestive tract. Olive oil is a major source of monounsaturated fats in Mediterranean countries, but also an important source of several micronutrients and food components that could be involved in cancer prevention (Pelucchi et al., 2011a). A risk-lowering diet for cancer would not only involve increasing the intake of fruit and vegetables and reducing the consumption of red meat (Hu et al., 2011b) but also the use of whole-grain carbohydrates in contrast to refined ones, and olive oil and other unsaturated fats instead of saturated ones.
The Mediterranean diet fulfils all these requirements as indicated in the well-known pyramid model (Fig. 1) (Bach-Faig et al., 2011). On the basis of data published by Trichopoulou et al. (2000), up to 25% of colorectal cancer, 15% of breast cancer and 10% of prostate, pancreas and endometrial cancer could be prevented if the populations of high-income countries could shift to the traditional healthy Mediterranean diet.
Moreover, the Mediterranean diet may help regulate body weight, which is a priority in cancer prevention. No increase in overweight and obesity has been observed in Italy and France in the recent past (Gallus et al., 2006). From the point of view of potential preventive mechanisms, the analyses of the dietary pattern of the typical Mediterranean diet have shown a number of protective aspects such as a balanced ratio of n-6/n-3 essential fatty acids, high amounts of fibre, antioxidants (especially polyphenols from olive oil and wine) and vitamins E and C, some of which have been shown to be associated with a lower risk of cancer (Simopoulos, 2004).
Alcohol and the risk of cancer
A total of 400 000 cases of cancer were attributable to alcohol drinking worldwide in 2002, representing 3.6% of all cancers (5.2% in men and 1.7% in women). The corresponding figure for mortality is 250 000 deaths (3.5% of all cancer deaths). This proportion is particularly high among men in Central and Eastern Europe. Among women, breast cancer comprises 60% of alcohol-attributable cancers (Boffetta and Hashibe, 2006; Boffetta et al., 2006). The consumption of alcoholic beverages increases, among others, the risk of cancers of the mouth and pharynx (apart from cancers of the salivary glands and nasopharynx) (Goldstein et al., 2010), oesophagus (squamous cell carcinoma) and larynx. The risk increases approximately in proportion to the consumed amount. Alcoholic beverages act synergistically with smoking, each agent approximately multiplying the effects of the other, and the main component of alcoholic beverages that determines the risk of cancer is ethanol (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 2004). In Europe and North America, cancers of the upper respiratory and digestive tracts are rare in the absence of smoking, and only very few studies have included a sufficient number of cases to provide useful information about the effect of alcohol by itself. There is no reason to assume that tobacco smoke is the only carcinogenic agent to which the human upper respiratory and digestive tracts are exposed, and ethanol may be facilitating the effect of some other unrecognized carcinogenic agents in nonsmokers. Acetaldehyde is a carcinogenic metabolite of alcohol (Doll, 1998; Baan et al., 2007; Secretan et al., 2009; Matsuo et al., 2012).
Heavy drinking is commonly associated with poor nutrition and this also increases the risk of cancer (particularly of pharyngeal and oesophageal cancer, but also of laryngeal cancer) in heavy drinkers (Doll, 1998). Cohort and case–control studies have consistently suggested a direct relation between consumption of alcohol and colorectal cancer. The relation, however, is moderate, the risk for both colon and rectal cancer being about 50% increased with high levels of alcohol consumption (Baan et al., 2007; Secretan et al., 2009).
Alcohol drinking is strongly related to cirrhosis and is associated with primary liver cancer. The relation is difficult to examine because most alcohol-related liver cancers arise from cirrhotic degeneration, which in turn may lead to a reduction in alcohol drinking.
A recent meta-analysis has presented strong evidence for the absence of a role of moderate drinking in pancreatic carcinogenesis, as opposed to an increased risk for heavy alcohol drinking. Given the moderate increase in risk and the low prevalence of heavy drinkers in most populations, alcohol appears to be responsible only for a small fraction of all pancreatic cancers (Tramacere et al., 2010).
For breast cancer, Italian data, on the basis of a validated alcohol consumption questionnaire and a female population with a relatively high alcohol consumption, confirmed that alcohol drinking is moderately related to the risk of breast cancer. This association could explain 12% (95% confidence interval, 5–19%) of breast cancers in Italy, thus representing one of the major avoidable risk factors for this neoplasm (Ferraroni et al., 1998). The association between alcohol consumption and the risk of cancer for those sites for which sufficient or limited evidence for carcinogenicity is available (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 2010) has been reviewed recently (Pelucchi et al., 2011b). On the basis of the data collected, it was concluded that the restriction of alcohol drinking to the limits indicated by the European Code Against Cancer (Boyle et al., 2003) (i.e. 20 g/day for men and 10 g/day for women) would be associated with a 90% reduction in cancers and cancer deaths that could be attributed to alcohol in men and over 50% of alcohol-attributable cancers in women. As a consequence, about 330/360 000 cancer cases and about 200/220 000 cancer deaths can be avoided worldwide every year (Boffetta et al., 2006). Avoidance or limitation of alcohol consumption to two drinks/day in men and one drink/day in women is therefore a global public health priority.
Mediterranean way of drinking and cancer
Alcohol consumption was traditionally high in Mediterranean countries, particularly in France and Italy, but substantial declines have been observed over the last three decades. The pattern and problem of alcohol drinking is also peculiar in these countries, with regular (rather than binge) drinking mostly at meals, and with wine being the most common type of alcoholic beverage in most regions. Excess consumption of alcohol has major implications for the risk of cirrhosis and a few cancer sites, including those of the upper digestive and respiratory tracts. The incidence of and mortality from these cancers were remarkably high in the 1970s and 1980s in France, northern Italy and Spain. The total alcohol-related deaths (liver disease, cancer and car accidents) were estimated at ∼25 000/year in Italy (5% of all deaths) and over 50 000 (10% of all deaths) in France in the 1990s. Now these estimates are probably about 50% lower, because of the substantial (over 50%) decrease in alcohol consumption. This is not only because of declined mortality from cirrhosis and accidents but also because alcohol-related cancer mortality has been declining in France and Italy (Arfè et al., 2011). Now the highest rates are reported in Central and Eastern Europe. In terms of risk assessment, high levels of alcohol consumption (i.e. more than four drinks/day) result in a substantial risk of cancer at several sites, whereas lower levels of consumption result in a moderately increased risk for various cancers.
At the same time, moderate alcohol consumption can exert protective effects against Hodgkin lymphoma and certain types of heart disease, and in particular of ischaemic heart disease (Tramacere et al., 2012). Taking into account the favourable and unfavourable effects of alcohol on health, sensible individual advice should be provided on the recommended limits to alcohol drinking: these limits should not exceed 30 g of ethanol/day (i.e. about two drinks of beer, wine or spirits a day, meals included) for men and 15 g (one drink) for women.
Red wine, which is typically consumed in Mediterranean countries, contains a complex mixture of potentially preventive bioactive compounds (predominantly phenolic) and in particular flavonols such as myricetin, kaempferol and the predominant quercetin, the flavan-3-ol monomers catechin and epicatechin, the oligomeric and polymeric flavan-3-ols or proanthocyanidins, various highly coloured anthocyanins, various phenolic acids (gallic acid, caftaric acid, caffeic acid, p-coumaric acid) and the stilbene resveratrol (Guilford and Pezzuto, 2011; Giacosa et al., 2012). Recent advances in viticulture and oenology research have allowed an increase in the concentration of phenolic compounds in grapes and wines (Cagnasso et al., 2008; Zamboni et al., 2010). Highly tannic red wines can contain up to 3 g of total polyphenols/l and the amount of catechin and epicatechin derivatives, including oligomeric procyanidins, can even reach ∼800 mg/l (200 mg in two glasses, i.e. 2.86 mg/kg for a man with a body weight of 70 kg) (Landrault et al., 2001). The amount of resveratrol is ∼5 mg/l of wine (1.25 mg in two glasses of wine, i.e. 18 µg/kg for a man with body weight of 70 kg) (Stervbo et al., 2007). Moderate red wine drinkers will consume polyphenols at levels well above the population average. Resveratrol inhibits the proliferation of human cancer cell lines (Aggarwal et al., 2004; Baur and Sinclair, 2006; Vidavalur et al., 2006; Opie and Lecour, 2007; Harikumar and Aggarwal, 2008; Raval et al., 2008; Saiko et al., 2008) and, similar to curcumin and epigallocatechin gallate, it modulates the effects of deregulated cell cycle checkpoints (Meeran and Katiyar, 2008). A Danish cohort study of 156 patients with upper digestive tract cancers suggested that wine drinkers may be at a lower risk than those who have a similar intake of beer or spirits (Grønbaek et al., 1998; Gronbaek, 2002). Other studies, however, have shown inconsistent results (Boffetta and Hashibe, 2006).
More recently, in a study of 380 000 Americans, a Med-Diet score defined by high intake of fruits, vegetables, nuts, grains and fish, a low intake of dairy and meat, and 5–25 g/day of alcohol showed a reduction in mortality from cardiovascular disease, in both men and women, when the highest versus the lowest score tertiles were compared (Mitrou et al., 2007). This study also confirmed that the Mediterranean food pattern is associated with decreased cancer mortality (Mitrou et al., 2007).
Grinzane consensus on ‘Mediterranean diet and cancer prevention: food and wine for a healthy lifestyle’
A forum held in Grinzane Cavour (Italy) in November 2011 explored the crucial questions of how to modify the risk of cancer by the diet and resulted in the following consensus statement, signed by the authors of the present editorial: (a) the Mediterranean diet is characterized by the use of olive oil, frequent consumption of fruit and vegetables, fish, pulses and unrefined cereals, moderate intake of dairy products and a low intake of red and processed meat, with a moderate consumption of wine at meals. Nuts, spices and herbs are commonly used. (b) The Mediterranean diet is associated with a reduced risk of cardiovascular disease and cancer. (c) If the Mediterranean diet were introduced in countries with a typical western diet, the overall risk of cancer could be reduced by 10% and in particular the risk of colorectal and other digestive tract cancers could be reduced by up to 25%. (d) The biological mechanisms for cancer prevention associated with a Mediterranean diet have been related to the favourable effect of a balanced ratio of omega 6 and omega 3 essential fatty acids and the high amounts of fibre, antioxidants and polyphenols found in fruit, vegetables, olive oil and wine. (e) The Mediterranean diet also involves a ‘Mediterranean way of drinking’, that is, a regular, moderate consumption of wine mainly with food (up to two glasses a day for men and one glass for women). This pattern of drinking increases longevity, reduces the risk of cardiovascular disease and does not markedly influence the overall risk of cancer.
The work of C.L.V., E.N. and C.P. was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC).
Conflicts of interest
There are no conflicts of interest.
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24:2783–2840
Arfè A, Malvezzi M, Bertuccio P, Decarli A, La Vecchia C, Negri E. Cancer mortality trend analysis in Italy, 1970–2007. Eur J Cancer Prev. 2011;20:364–374
Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011;343:d6617
Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007;8:292–293
Bach-Faig A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Dernini S, et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 2011;14:2274–2284
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506
Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7:149–156
Boffetta P, Hashibe M, La Vecchia C, Zatonski W, Rehm J. The burden of cancer attributable to alcohol drinking. Int J Cancer. 2006;119:884–887
Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, et al. European Code Against Cancer and scientific justification: third version (2003). Ann Oncol. 2003;14:973–1005
Cagnasso E, Rolle L, Caudana A, Gerbi V. Relationship between grape phenolic maturity and red wine phenolic composition. Ital J Food Sci. 2008;20:365–380
Calle E, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591
Doll R. Epidemiological evidence of the effects of behavior and environment on the risk of human cancer. Recent Results Cancer Res. 1998;154:3–21
Ferlay J, Parkin DM, Steliarova-Foucher I. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–781
Ferraroni M, Decarli A, Franceschi S, La Vecchia C. Alcohol consumption and risk of breast cancer: a multicentre Italian case control study. Eur J Cancer. 1998;34:1403–1409
Gallus S, Colombo P, Scarpino V, Zuccaro P, Negri E, Apolone G, et al. Overweight and obesity in Italian adults 2004, and an overview of trends since 1983. Eur J Clin Nutr. 2006;60:1174–1179
Giacosa A, Adam-Blondon AF, Baer-Sinnott S, Barale R, Bavaresco L, Di Gaspero G, et al. Alcohol and wine in relation to cancer and other diseases. Eur J Cancer Prev. 2012;21:103–108
Goldstein BY, Chang SC, Hashibe M, La Vecchia C, Zhang ZF. Alcohol consumption and cancer of the oral cavity and pharynx from 1988 to 2009: an update. Eur J Cancer Prev. 2010;19:431–465
Gronbaek M. Alcohol, type of alcohol, and all-cause and coronary heart disease mortality. Ann N Y Acad Sci. 2002;957:16–20
Grønbaek M, Deis A, Becker U, Hein HO, Schnohr P, Jensen G, et al. Alcohol and mortality: is there a U-shaped relation in elderly people? Age Ageing. 1998;27:739–744
Guilford JM, Pezzuto JM. Wine and health: a review. Am J Enol Vitic. 2011;62:471–486
Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle. 2008;7:1020–1035
Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L. Dietary transfatty acids and cancer risk. Eur J Cancer Prev. 2011a;20:530–538
Hu J, La Vecchia C, Morrison H, Negri E, Mery L. Salt, processed meat and the risk of cancer. Eur J Cancer Prev. 2011b;20:132–139
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. 2004;Vol. 83 Lyon, France International Agency for Research on Cancer
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Alcohol consumption and ethyl carbamate. 2010;Vol. 96 Lyon, France International Agency for Research on Cancer
Karim-Kos HE, De Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–1389
Landrault N, Poucheret P, Ravel P, Gasc F, Cros G, Teissedre PL. Antioxidant capacities and phenolic levels of Franch wines from different varieties and vintages. J Agric Food Chem. 2001;49:3341–3348
La Vecchia C. The future of cancer in Europe. Eur J Canc Prev. 2011;20:253–254
La Vecchia C, Favero A, Franceschi S. Monounsaturated and other types of fat and the risk of breast cancer. Eur J Cancer Prev. 1998;7:461–464
Matsuo K, Rossi M, Negri E, Oze I, Hosono S, Ito H, et al. Folate, alcohol, and aldehyde dehydrogenase-2 polymorphism and the risk of oral and pharyngeal cancer in Japanese. Eur J Cancer Prev. 2012;21:193–198
Meeran SM, Katiyar SK. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci. 2008;13:2191–2202
Mitrou PN, Kipnis V, Anne CM, Thiébaut I, Reedy J, Subar A, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med. 2007;167:2461–2468
Opie LH, Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J. 2007;28:1683–1693
Pelucchi C, Bosetti C, Negri E, Lipworth L, La Vecchia C. Olive oil and cancer risk: an update of epidemiological findings through 2010. Curr Pharm Des. 2011a;17:805–812
Pelucchi C, Tramacere I, Boffetta P, Negri E, La Vecchia C. Alcohol consumption and cancer risk. Nutr Cancer. 2011b;63:983–990
Raval AP, Lin HW, Dave KR, Defazio RA, Della Morte D, Kim EJ, et al. Resveratrol and ischemic preconditioning in the brain. Curr Med Chem. 2008;15:1545–1551
Saiko P, Pemberger M, Horvath Z, Savinc I, Grusch M, Handler N, et al. Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. Oncol Rep. 2008;19:1621–1626
Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens – part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033–1034
Simopoulos AP. The traditional diet of Greece and cancer. Eur J Cancer Prev. 2004;13:219–230
Stervbo U, Vang O, Bonnesen C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem. 2007;101:449–457
Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010;126:1474–1486
Tramacere I, Pelucchi C, Bonifazi M, Bagnardi V, Rota M, Bellocco R, et al. A meta-analysis on alcohol drinking and risk of Hodgkin lymphoma. Eur J Cancer Prev. 2012;21:268–273
Trichopoulou A, Lagiou P, Kuper H, Trichopoulos D. Cancer and Mediterranean dietary traditions. Cancer Epidemiol Biomarkers Prev. 2000;9:869–873
Van Kruijsdijk RC, Van Der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009;18:2569–2578
Vidavalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol. 2006;11:217–225
Zamboni A, Di Carlim M, Guzzo F, Stocchero M, Zenoni S, Ferrarini A, et al. Identification of putative stage specific grapewine berry biomarkers and omics data integration into networks. Plant Phisiol. 2010;154:1439–1459